QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.105.092742v1 316/1/423    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Watson, Michael. J. Articles by Chang, K.-J. Search for Related Content PubMed PubMed Citation Articles by Watson, Michael. J. Articles by Chang, K.-J.

CARDIOVASCULAR

ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic Acid], A Novel Nonpeptide Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects

Enhance Biotech Inc., Durham, North Carolina (M.J.W., J.D.S.H., S.J.O., K.W., W.P., K.-J.C.); Medical College of Wisconsin, Department of Pharmacology and Toxicology, Milwaukee, Wisconsin (G.J.G.); and Alza Corporation, Mountain View, California (P.J.G.)

A novel -receptor selective compound, ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2, 5-dimethylpiperazin-1-ylmethyl)benzoic acid], was evaluated for activity on infarct size in a rat model of acute myocardial infarction. ARD-353 was characterized as having receptor selectivity using radioligand binding and had no apparent selectivity between receptor subtypes as determined by [³H] cyclic [D-Pen²,D-Pen⁵]enkephalin (₁) and [³H]Deltorphin II (₂) competition binding. ARD-353 also showed selective receptor agonist activity in mouse-isolated vas deferens. There was no evidence of any seizure-like convulsions when ARD-353 was administered to mice either i.v. or p.o., implying minimal penetration of the blood-brain barrier. ARD-353 decreased infarct size in a left anterior descending coronary artery (LAD) occlusion model of myocardial infarction. In animals pretreated with ARD-353 (i.v.) and then subjected to 30 min of LAD occlusion followed by 90 min of reperfusion, infarct size was reduced in a dose-dependent manner compared with vehicle-treated controls. The effects of ARD-353 on infarct size were blocked by the ₁-opioid selective antagonist 7-benzylidenenaltrexone, indicating a significant role for the ₁-opioid receptor in the cardioprotective mechanism of ARD-353. ARD-353 (0.3 mg/kg i.v.) produced significant protection when administered 5 min and 12 and 48 h before ischemic insult or when given immediately after the ischemic insult (at the start of reperfusion). Given the lack of central nervous system effects and beneficial efficacy in the rat model of myocardial ischemia, it is felt that ARD-353 is the first nonpeptide -receptor agonist with true potential for clinical use before surgically induced ischemia or in an emergency setting.

Address correspondence to: Jonathon Holt, Enhance Biotech Inc., 631 United Drive, Suite 200, Durham, NC 27713. E-mail: jholt{at}enhancebiotech.com